PYX-201, an antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets ...

About PYX-201 PYX-201, an antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

So, XB002 was anti-tissue factor targeting ADC with a microtubule targeting payload. XB371 uses the same antibody with a drug antibody ratio of 8 and a topoisomerase inhibitor drug payload.

against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company ...

UA62784 is one of few compounds that selectively target PDAC cells. It is a novel highly potent microtubule inhibitor with enormous cytotoxicity whether used alone or with other MDAs. Its cytotoxicity ...

Live imaging of microtubule polymerization in pseudo-unipolar DRG neuron ... 140 mM sodium chloride diluted in Tris-EDTA buffer pH 8.0, and containing protease inhibitors (#04693124001, Roche)).